Evidence map›Paper›PMID 38319333›Full record

ArticleJAMA2024

Serum Urate and Recurrent Gout.

Natalie McCormick, Chio Yokose, Gregory J Challener, Amit D Joshi, Sruthi Tanikella, Hyon K Choi

Open access · greenAbstract read
In one paragraph

Article in JAMA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Preinfusion Glucocorticoid Reduction and Elimination in Patients With Uncontrolled Gout on Pegloticase and Methotrexate: A Case Series.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Quality Care Assessment in Gout.Current rheumatology reports · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Spatiotemporal landscape of kidney in a mouse model of hyperuricemia at single-cell level.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Natalie McCormickRheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
Chio YokoseRheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
Gregory J ChallenerDepartment of Medicine, Harvard Medical School, Boston, Massachusetts.
Amit D JoshiChanning Division of Network Medicine, Boston, Massachusetts.
Sruthi TanikellaRheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
Hyon K ChoiRheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
Harvard University · USMassachusetts General Hospital · US

Funding

The Effects of Urate Lowering Therapy on Inflammation, Endothelial function, andP50AR060772 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TERKELTAUB, ROBERT A. · 2012 to 2021
$12.8M
Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9M
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUTR01AR065944 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI CHOI, HYON K · 2013 to 2025
$4.2M
Personalized Comorbidity-Integrated Gout CareK23AR081425 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Chio Yokose · 2023 to 2026
$704k
Metabolic syndrome, chronic inflammation, and gout: a multi-omics approachR00AR080243 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI Natalie McCormick · 2025 to 2026
$461k
Metabolic syndrome, chronic inflammation, and gout: a multi-omics approachK99AR080243 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI MCCORMICK, NATALIE · 2022 to 2023
$188k
NIAMS NIH HHS K23 AR081425NIAMS NIH HHS K99 AR080243NIAMS NIH HHS P50 AR060772NIAMS NIH HHS R00 AR080243NIAMS NIH HHS R01 AR065944NIAMS NIH HHS T32 AR007258
6 · The paper itself

Abstract

Importance: Approximately 12 million adults in the US have a history of gout, but whether serum urate levels can help predict recurrence is unclear. Objective: To assess associations of a single serum urate measurement with subsequent risk of acute gout flares and subsequent risk of hospitalizations for gout among patients in the UK with a history of gout. Design, Setting, and Participants: This retrospective study included patients with a history of gout identified from the UK between 2006 and 2010 who were followed up through Primary Care Linked Data medical record linkage until 2017 and through the Hospital Episode Statistics database until 2020. Exposures: Serum urate levels at enrollment. Main Outcome and Measure: Rate of recurrent acute gout, ascertained by hospitalization, outpatient, and prescription/procedure records, and adjusted rate ratios using negative binomial regressions. Results: Among 3613 patients with gout (mean age, 60 years; 3104 [86%] men), 1773 gout flares occurred over a mean follow-up of 8.3 years. Of these, 1679 acute gout flares (95%) occurred in people with baseline serum urate greater than or equal to 6 mg/dL and 1731 (98%) occurred in people with baseline serum urate greater than or equal to 5 mg/dL. Rates of acute gout flares per 1000 person-years were 10.6 for participants with baseline urate levels less than 6 mg/dL, 40.1 for levels of 6.0 to 6.9 mg/dL, 82.0 for levels of 7.0 to 7.9 mg/dL, 101.3 for levels of 8.0 to 8.9 mg/dL, 125.3 for urate levels of 9.0 to 9.9 mg/dL, and 132.8 for levels greater than or equal to 10 mg/dL. Rate ratio of flares were 1.0, 3.37, 6.93, 8.67, 10.81, and 11.42, respectively, over 10 years (1.61 [1.54-1.68] per mg/dL). Rates of hospitalization per 1000 person-years during follow-up were 0.18 for those with baseline serum urate less than 6 mg/dL, 0.97 for serum urate of 6.0 to 6.9 mg/dL, 1.8 for serum urate of 7.0 to 7.9 mg/dL, 2.2 for serum urate of 8.0 to 8.9 mg/dL, 6.7 for serum urate of 9.0 to 9.9 mg/dL, and 9.7 for serum urate greater than or equal to 10 mg/dL. Rate ratios of hospitalization for gout, adjusting for age, sex, and race were 1.0, 4.70, 8.94, 10.37, 33.92, and 45.29, respectively (1.87 [1.57-2.23] per mg/dL). Conclusions and Relevance: In this retrospective study of patients with a history of gout, serum urate levels at baseline were associated with the risk of subsequent gout flares and rates of hospitalization for recurrent gout. These findings support using a baseline serum urate level to assess risk of recurrent gout over nearly 10 years of follow-up.

Indexed as

GoutUric AcidDatabases, FactualFemaleFollow-Up StudiesHospitalizationHumansMaleMiddle AgedRecurrenceRetrospective StudiesRisk AssessmentSymptom Flare UpUnited KingdomUric Acid

Identifiers

PMID38319333
PMCPMC10848075
OpenAlexW4391562060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.